Iga Swiatek, the world number two from Poland, who has won five Grand Slam titles in her career, has accepted a one-month suspension after a doping violation. The 23-year-old is understood to have tested positive for a heart medication called Trimetazidine (TMZ), in an out-of-competition sample, which was taken in August of 2024 during the time she was the top ranked women’s singles player in the world.
As per the report from the BBC, it has been confirmed by the International Tennis Integrity Agency (ITIA) on Thursday, November 28, that an investigation found that the doping violation happened in Iga Swiatek’s case due to a contaminated regulated medication, which was manufactured in Poland. With that, it was ruled that she had “no significant fault or negligence” for failing the dope test this past summer.
Iga Swiatek's one-month suspension will end on December 4 after serving 22 days earlier
Notably, Iga Swiatek was provisionally suspended from tennis from September 12 onwards before a successful appeal against the decision meant that she had to miss out on playing only three tournaments, namely Korea Open, China Open, and Wuhan Open. After their investigation into the matter, ITIA offered the Polish tennis star a one-month suspension, which was accepted by her just a day ago.
Due to the provisional suspension in Iga Swiatek’s case, which was lifted on October 4 after being imposed on September 22, only eight days are remaining for her to serve as part of her one-month suspension, which would go down from November 27 to December 4. Moreover, in a latest post on her official Instagram account, an emotional Iga Swiatek addressed the doping violation in detail, calling it the worst experience of her life.
“Out of respect for my fans and the public, I’m sharing all the details of this longest and toughest tournament of my career. My biggest hope is that you will stay with me,” she concluded.
